BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Actelion Ltd. (ALIOF.PK) Surges as Hypertension Drug Meets Clinical Goal


4/30/2012 6:55:48 AM

Actelion Ltd ATLN.VX Monday said a late-clinical study of its hypertension drug macitentan has met its primary end point, and it will seek global registration of the remedy by the fourth quarter of the year. The approval of macitentan is seen as key for Actelion's future as the company stands to lose the patent protection of its key drug, Tracleer for pulmonary hypertension, in 2015. Tracleer makes up the bulk of Actelion's revenue but competition from generic products, once the drug loses its patent, could cut more than 50% of the medicine's revenue, analysts say.

Read at Market Watch
Read at BusinessWeek
Read at Reuters
Read at Wall Street Journal

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES